All In Biotech

BLA 022575 · Shire Human Genetic

Vpriv

Velaglucerase Alfa · Intravenous · Hydrolytic Lysosomal Glucocerebroside-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jul 10, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Feb 26, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

8 Phase 3, 0 recruiting

FAERS reports

2,052

1,718 serious, 280 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement and after extended duration of therapy. Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue VPRIV and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full...

What it is approved for

From the label in effect Nov 26, 2024.

VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. ( 1 )

Mechanism: Gaucher disease is an autosomal recessive disorder caused by mutations in the GBA gene, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency causes an accumulation of glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or "Gaucher cells". Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside. In clinical trials VPRIV reduced...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 21, 2013 Supplement 12 · Efficacy OrphanLetterLabel
  • Feb 26, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
2 products under this application
  • VPRIV · VELAGLUCERASE ALFA 400 UNITS/VIAL · INJECTABLE, INTRAVENOUS · Prescription
  • VPRIV · VELAGLUCERASE ALFA 200 UNITS/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Velaglucerase Alfa" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • inappropriate schedule of product administration212
  • product dose omission issue198
  • covid-19167
  • fatigue154
  • death127
  • pyrexia114
  • fall112
  • malaise111
  • weight increased106
  • headache105
  • infusion related reaction102
  • nausea98

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201012
201121
201243
201374
2014114
2015101
201697
201784
2018141
2019158
2020160
2021313
2022224
2023154
2024173
2025112
202671

Recalls

1 FDA enforcement reports for this application.

  • Mar 14, 2014 · Class I · Terminated

    Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vpriv (Velaglucerase Alfa)

2024 spending

$9.3M

Beneficiaries

24

285 claims

Per beneficiary

$386,843

$1,452.93 per unit

View as table
YearSpending
2020$8,205,400
2021$8,478,535
2022$8,532,016
2023$9,262,628
2024$9,284,239

Part B: Vpriv (Velaglucerase Alfa) · HCPCS J3385

2024 spending

$32.7M

Beneficiaries

107

2,091 claims

Per beneficiary

$305,343

2024 ASP limit $368.73 per unit

View as table
YearSpending
2020$25,304,812
2021$27,094,729
2022$28,849,851
2023$30,900,225
2024$32,671,660

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.